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Summary
To investigate whether the formation of vascular en-
dothelial growth factor (VEGF) influences erythropoi-
etin (EPO) expression in physiological conditions, we
injected into the left lateral cerebral ventricle of the
Mongolian gerbil an adeno-associated virus (AAV) vec-
tor capable of expressing the 165-amino-acid isoform
of VEGF (VEGF165). Twelve and 18 days after AAV vec-
tor injection, the experimental animals were sacrificed
and expression of EPO was evaluated through im-
munohistochemical analysis of both the hippocampus
and the frontal cortex. 
We observed that VEGF165 induces EPO expression in
the hippocampal pyramidal layers and in the frontal
cortex of the gerbil, particularly after the 18th day fol-
lowing treatment with the vector, which suggests that
VEGF165 could act as a hypoxic-like signal for EPO pro-
duction. This finding could help to clarify the function-
al role of EPO and the molecular mechanisms by which
VEGF might mediate its effects in the brain. 
KEY WORDS: adeno-associated virus, brain, erythropoietin,
VEGF165.
Introduction
It is well known that vascular endothelial growth factor
(VEGF) is primarily involved in angiogenesis (1), partic-
ularly following brain hypoxia; moreover its expression,
triggered within a few hours in the experimental model
of brain ischemia induced by middle cerebral artery oc-
clusion, persists for days to weeks (2). Accordingly, after
an ischemic stroke, brain tissue has been reported to
show up-regulation of VEGF mRNA in neurons, astro-
cytes and endothelial cells and marked expression of
VEGF receptors in blood vessels (3).
This appears to be supported by previous experimental
observations showing that brain ischemia induces ex-
pression of HIF-1α and consequently of VEGF and its
receptors (5). 
Erythropoietin (EPO) is a primary regulator of erythro-
poiesis and is fundamentally produced by the kidney in
adults and by hepatocytes in the foetus in response to
hypoxia (6). 
However, previous experimental findings demonstrated
that EPO and its receptor are constitutively expressed in
the brain of a wide variety of mammals, including hu-
mans, suggesting a direct role for this hormone in the
central nervous system (7). 
Interestingly, it has been shown that both VEGF and
EPO exert neuroprotective effects in both in vitro and 
in vivo experimental models (8-12), probably through
the common oxygen-sensing pathway represented by 
HIF-1α (13). 
These findings, taken together, could indicate a possible
cross-talk between VEGF and EPO in the regulation of
physiological and pathological events in the brain.
However, to date, the exact molecular mechanisms by
which VEGF might mediate its actions in the central
nervous system, and the possible implications for EPO
in this regard, are not well understood.
In view of these preliminary considerations, we injected
into the gerbil brain, without hypoxic stimulus and at dif-
ferent time points, an adeno-associated virus (AAV) vec-
tor capable of expressing the 165-amino-acid isoform of
VEGF (VEGF165). Our aim was to investigate, in dis-
Functional Neurology 2006; 21(2): 87-91 87
Vascular endothelial growth factor induces brain
erythropoietin expression?
crete brain regions, namely the hippocampus and frontal
cortex, whether VEGF can induce EPO production. 
It was felt that the chosen approach (gene transfer
through an AAV vector) may better show the direct mo-
lecular effects of VEGF in the brain and help to clarify its
mechanism of action.
Materials and methods
Two recombinant AAV (rAAV) vectors were obtained ex-
pressing the LacZ reporter gene (control gene) and the
cDNA for VEGF165 under the control of the strong and
constitutive cytomegalovirus immediate early promoter.
The purified viral preparations used in this work had par-
ticle titres of 1×1012 viral genomes per ml.
Male Mongolian gerbils, weighing 60-70 g, housed four
to a cage at a constant room temperature of 21-22°C
under a light/dark cycle of 12/12 h (7.00 a.m./7.00 p.m.)
with free access to food and water ad libitum, were
used. 
Adaptation and experiments were carried out in accor-
dance with internationally accepted principles and with
Italian laws concerning the care and the use of laborato-
ry animals, as well as with the European Communities
Council Directive 86/609/EEC, of 24 November 1986.
Twelve and 18 days before decapitation under general
anaesthesia, gerbils were anesthetized with chloral hy-
drate (2.5%), placed in a stereotaxic apparatus and a
guide cannula was implanted into the left lateral cerebral
ventricle according to the Thiessen and Yahr atlas (14).
The animals were then randomized to treatment with
rAAV-LacZ (control) or with rAAV-VEGF165 (0.5-25 U) in
10 µl of artificial cerebrospinal fluid injected into the left
lateral cerebral ventricle. 
Immunohistochemistry was performed in animals sacri-
ficed with light chloral hydrate anaesthesia. Brains were
removed and 40-µm thick brain coronal sections were
cut using a freezing microtome and stored at 4°C. A set
of sections, regularly spaced through the brain, was
mounted and stained with thionin 0.25% for histological
identification of nervous structures, drawing analogies
with the rat brain according to the Thiessen and Yahr at-
las (14). The remaining sections were used for immuno-
histochemical experiments. Biotinylated goat anti-rabbit
primary antiserum for EP was used (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA). Free-float-
ing sections through the brain were rinsed in tris-
buffered saline of pH 7.6 (TBS) and incubated overnight
with the primary antibodies diluted in TBS containing 2%
normal goat serum (NGS). Sections were then rinsed
and incubated for 60 min with biotinylated goat anti-rab-
bit serum (diluted 1:200 in TBS containing 1% NGS); 60
min with avidin-biotinylated peroxidase complex (diluted
1:100) in TBS; and 4-8 min with a solution of 3,3’-di-
aminobenzidine tetrahydrochloride 0.5 M. Sections
were finally mounted, air-dried and cover-slipped for mi-
croscopic observation. No immunostaining was ob-
served in control tissue. Computer-assisted densitome-
try was used for quantitative estimation of immunostain-
ing. For this purpose, the optical density of images was
analyzed in a range of 256 grey level values. Micro-
scope illumination and video-amplifier parameters were
carefully adjusted to avoid saturation of images. These
conditions were kept constant.
Statistical analysis
All statistical procedures were performed using SPSS
statistical software package, release 6.1.3 (SPSS Inc.,
Chicago, IL, USA). Data analysis was performed using
one-way analysis of variance (ANOVA) with Scheffè
post-hoc test for multiple comparisons. Each value rep-
resents the mean ± SD of six animals. Statistical signif-
icance was set at p≤0.05.
Results
The animals challenged with rAAV-LAcZ (controls)
showed very low immunopositivity for EPO in the CA1
and CA3 areas of the left hippocampus and in the left
frontal cortex (Fig.s 1, 2, 3, 4A, 4C). 
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Figure 2 - Effects on immunostaining for EPO in the CA3 area of
gerbils: (i) following rAAV-LacZ treatment (controls), (ii) 12 days
after rAAV-VEGF165 administration, (iii) 18 days after rAAV-
VEGF165 administration. Each column represents the mean ± SD
of five to six animals. *p<0.01 vs sham + rAAV-LacZ.
Figure 1 - Effects on immunostaining for EPO in the CA1 area
of gerbils: (i) following rAAV-LacZ treatment (controls), (ii) 12
days after rAAV-VEGF165 administration (iii) 18 days after rAAV-
VEGF165 administration. Each column represents the mean ±
SD of five to six animals. *p<0.01 vs sham + rAAV-LacZ.






































By contrast, in gerbils 12 days and 18 days after rAAV-
VEGF165 administration, the computer-assisted densito-
metry of microscopical sections revealed an immunopos-
itivity for EPO in the left frontal cortex and the left hip-
pocampus (Fig.s 1, 2, 3). 
In particular, the strongest immunopositivity was ob-
served 18 days after rAAV-VEGF165 treatment in py-
ramidal cell layers of the left hippocampus (namely
CA1 and CA3 areas) and in the left frontal cortex (Fig.
4B, 4D). 
Discussion
There is experimental evidence suggesting that VEGF
could have beneficial effects on ischemia-induced brain
injury (15,16); however, cerebral ischemia caused by
severe hypoxia occurs in a series of steps, suggesting
the possible involvement of other mediators in the neu-
roprotective effects of VEGF.
In this regard, acute hypoxic brain damage has been as-
sociated with increased brain EPO expression (17); in-
deed, EPO is strategically modulated in many cell types
(neurons, endothelial and glial cells) as a function of the
duration of the brain ischemia (18) and its administration
prevents place navigation disability and cortical infarc-
tion in rats with permanent occlusion of the middle cere-
bral artery (19). Accordingly, different findings showed
VEGF and EPO in the gerbil brain
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Figure 3 - Effects on immunostaining for EPO in the frontal cor-
tex of gerbils: (i) following rAAV-LacZ treatment (controls), (ii) 12
days after rAAV-VEGF165 administration (iii) 18 days after rAAV-
VEGF165 administration. Each column represents the mean ± SD
of five to six animals. *p<0.01 vs sham + rAAV-LacZ.
Figure 4 - A) Slide of left hippocampus in a Mongolian gerbil sacrificed 18 days after injection of rAAV-LacZ into the left lateral cere-
bral ventricle. Absence of immunopositive EPO-elements. B) Immunostaining for EPO in section of left hippocampus in a Mongolian
gerbil sacrificed 18 days after injection of rAAV-VEGF165 (x10) into the left lateral cerebral ventricle. Several EPO neurons are clear-
ly marked black, denoting immunopositivity. C) Slide of left frontal cortex of a Mongolian gerbil sacrificed 18 days after injection of
rAAV-LacZ into the left lateral cerebral ventricle. No EPO-positive elements are displayed. D) Immunostaining of left frontal cortex of
a Mongolian gerbil sacrificed 18 days after injection of rAAV-VEGF165 (x10) into the left lateral cerebral ventricle. Several neurons




























constitutive presence of EPO and its receptor in neu-
rons, glial and endothelial cells (19), providing new in-
sights into a possible role for this hormone in the mam-
malian brain, even in the absence of hypoxic stimulus
(20,21).
Thus, we decided to evaluate, only in physiological con-
ditions (and thus without hypoxic stimulus), EPO ex-
pression in the Mongolian gerbil following the injection of
the AAV-VEGF vector capable of expressing VEGF165.
In this regard, VEGF presents four different isoforms,
VEGF121, VEGF165, VEGF189, VEGF206, which are gen-
erated by alternative splicing of mRNA (22).
Currently promising new strategies for gene delivery to
the brain (23) include the use of AAV vectors. These
vectors are derived from a non-pathogenic and wide-
spread defective Parvovirus and are able to transduce
both dividing and nondividing cells (24-26). Since rAAV
vectors are devoid of any viral genes, they elicit virtual-
ly no inflammatory or immune response in the sites of in-
jection (27).
Furthermore, AAV vectors boast several important fea-
tures, including the capacity to promote long-term ex-
pression of the gene transferred.
Our experimental data indicate that VEGF165 adminis-
tration in the left lateral cerebral ventricle of the gerbil, in
the absence of hypoxic stimulus, triggers EPO produc-
tion in the left hippocampus and the left frontal cortex.
Interestingly, we observed that EPO immunoreactivity
was also present in brain regions (i.e., right hippocam-
pus, thalamus) remote from the left cerebral ventricle,
although it was clearly and significantly higher in the
brain regions near the site of injection. These data are
very much in line with our previous finding that the
process of VEGF gene expression after gene delivery
was not limited to the left hippocampus, but extended to
the controlateral hippocampus and thalamus (16). 
In order to clarify this issue, vector expression in cere-
brospinal fluid in similar experiments investigating leptin
expression in brain tissue, as well as in the ependymal
cells lining the ventricular system, has been hypothe-
sized (28). 
In the present study, the animals that received rAAV-LacZ
(controls) showed very low immunopositivity for EPO in
all the brain regions observed (Fig.s 1, 2, 3, 4A, 4C),
while clear immunostaining for EPO was found in the left
frontal cortex and left hippocampus of animals treated
with VEGF165 (Fig.s 1, 2, 3, 4B, 4D), suggesting that this
isoform could, itself, act as an EPO synthesis inducing
factor. 
Furthermore, our data showed that EPO presents
marked expression 18 days after rAAV-VEGF injection,
predominantly in the pyramidal layers of the hippocam-
pus (CA1 and CA3 areas). Obviously, further experi-
ments are needed to test, in the same experimental mod-
el, the duration of EPO expression after rAAV-VEGF in-
jection. 
As mentioned above, we observed that EPO expression
was most evident within the hippocampus and the
frontal cortex. These are, in fact, regions vulnerable to
ischemia (especially the hippocampus) and, although
our experiments were carried out in the absence of hy-
poxic stimuli, we suggest that it is likely that VEGF, at
least in this isoform and in physiological conditions,
could act as a hypoxic-like signal for EPO production
only in brain regions that are impaired in pathological
conditions of hypoxia (i.e., stroke) (29-31). In addition,
the presence of specific EPO binding sites in these ar-
eas (32) further supports this idea suggesting that EPO
may play a crucial role as a polyfunctional rather than as
a monofunctional growth factor in the mammalian brain.
Again, our observations agree with a large body of liter-
ature indicating that the hypoxic stimulus/HIF-1α plays a
crucial role in pathological conditions of reduced avail-
ability of oxygen through the mutual functional activation
of VEGF and EPO (summarized in Fig. 5). 
In the light of these observations, it is possible to spec-
ulate that also in conditions where the hypoxic stimulus
is not present, the increased EPO expression in the hip-
pocampus and/or in other brain regions following VEGF
treatment could be directly related to the effects of
VEGF (Fig. 5). 
In conclusion, our results show, for the first time, that in
the absence of hypoxic stimuli, the production of VEGF
obtained through gene transfer can be associated with
EPO formation. These data, taken together, might help
to clarify a new possible synergic mechanism that could
explain possible protective properties of VEGF and a
polyfunctional role of EPO in different brain pathological
conditions. 
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